Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.

Chromatographic Methodologies for Analysis of Cocaine and Its Metabolites in Biological Matrices

Abstract: Cocaine is the main active alkaloid extracted from the leaves of the coca plant, Erythroxylum coca It is a widely abused psychotropic drug, for its immediate neurological effects, including euphoria, reduced fatigue and increased mental acuity and sexual desire (Devlin & Henry, 2008; Goldstein et al, 2009; Small et al, 2009) However, cocaine abuse is usually followed by many pathophysiological consequences, namely central and peripheral neurochemical changes that result in hypertension-related morbidity and mortality, including myocardial infarction and cerebrovascular accidents, as well as liver and kidney toxicity, tissue ischemia and adverse psychotic effects such as paranoia and hallucinations (Devlin & Henry, 2008; Glauser & Queen, 2007; Heard et al, 2008; Karch, 2005; Lombard et al, 1988; Ndikum-Moffor et al, 1998; Tang et al, 2009; White & Lambe, 2003)

An autopsy case of multiple psychotropic drug poisoning

Abstract: A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented. Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents. We conclude that the cause of death was due to the interaction of multiple psychotropic drugs.

Positron emission tomography in psychiatry.

Abstract: Positron emission tomography permits the study of human brain function. With a positron labelled tracer and a model for quantitation, regional brain metabolism and neuroreceptor characteristics can be determined with PET. Schizophrenia is the most extensively studied psychiatric disorder. Most studies have demonstrated decreased metabolic rates in wide areas of the brain. It is proposed that the metabolic changes observed in the brains of schizophrenic patients are due to a fundamental change in neuronal function. Fewer studies have been performed in other psychiatric disorders. Bipolar depressed patients probably have a decreased brain metabolism. Obsessive compulsive and panic disorders (if sensitive to lactate) have an increased brain metabolism. This is probably also the case for female anorectic patients. Alcohol dependent subjects with a long duration of abuse may have a decreased brain metabolism. Neuroreceptor studies with PET have in one study of psychotropic drug naive schizophrenic patients demonstrated an increase of D2-dopamine receptors. In another study no difference between controls and patients was found. Treatment of schizophrenic patients with conventional doses of neuroleptic drugs results in a D2 receptor occupancy of 65 to 85 per cent, suggesting that there is no need for high dose treatment in schizophrenic patients. The studies reviewed clearly demonstrate that PET is a valuable tool in psychiatric research.

Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008.

Abstract: There is little clinical data available about seizure rates in psychiatric inpatients, and there are no studies with reference data to the frequencies of antidepressant (AD) use for this important clinical population. This study investigates seizure rates during AD treatment in psychiatric inpatient settings, drawn from the transnational pharmacovigilance programme Arzneimittelsicherheit in der Psychiatrie (AMSP) in relation to the known frequencies of ADs used in the participating clinics. Comparisons are made to former publications and their limitations. Seventy-seven cases were identified with grand mal seizures (GMS) during AD treatment between 1993 and 2008, with a total number of 142,090 inpatients under surveillance treated with ADs in the participating hospitals. The calculated overall rate of reported seizures of patients during AD treatment in this collective is 0.05 % for ADs imputed alone or in combination with other psychotropic drug groups and 0.02 % when only ADs were given and held responsible for GMS. The patients receiving tri- or tetracyclic ADs (TCAs) had a 2-fold risk to develop a seizure as compared to the overall average rate in this sample. In 11 cases, there was only one AD imputed—the majority of these cases (9/11) were TCA. Monotherapy with selective serotonin reuptake inhibitors (SSRI) or dual serotonin and noradrenaline reuptake inhibitors (SNRI) were never imputed alone in this sample. The results of the study favour the assumption that SSRIs, noradrenergic and specific serotonergic antidepressants (NaSSA) and dual SNRI might be more appropriate than TCAs for the treatment of psychiatric patients with an enhanced seizure risk.

Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.